Literature DB >> 3114314

Management of failed cycles in an IVF/GIFT programme with the combination of a GnRH analogue and HMG.

J Smitz, P Devroey, P Braeckmans, M Camus, I Khan, C Staessen, L Van Waesberghe, A Wisanto, A C Van Steirteghem.   

Abstract

The addition of the gonadotropin releasing hormone (GnRH) agonist Buserelin to human menopausal gonadotrophin/human chorionic gonadotropin (HMG/HCG) during ovarian stimulation was evaluated in 23 cycles of 21 women who previously had unsuccessful IVF treatments when stimulated with clomiphene--HMG/HCG. No adverse effects of GnRH-agonist on folliculogenesis were seen. A mean number of 7.2 oocytes per retrieval was collected in 20 treatment cycles. Oocytes quality, fertilization and cleavage parameters were normal. Replacements by gamete intra-Fallopian transfer (GIFT) or IVF took place for 16 patients. Four patients became pregnant in their treatment cycle, one aborted. For 8 patients 18 embryos were cryopreserved, one transfer of a frozen--thawed embryo in a subsequent natural cycle led to a pregnancy. Inadequate luteal phases were constantly observed when supplementation was omitted. Further study is required to confirm that systematic luteal support improves the pregnancy rate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3114314     DOI: 10.1093/oxfordjournals.humrep.a136540

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  19 in total

1.  In vitro fertilization programmed for weekday-only oocyte harvest: analysis of outcome based on actual retrieval day.

Authors:  A Ben-Chetrit; S Senoz; E M Greenblatt
Journal:  J Assist Reprod Genet       Date:  1997-01       Impact factor: 3.412

Review 2.  Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomes.

Authors:  Israel Ortega; Juan A García-Velasco; Antonio Pellicer
Journal:  J Assist Reprod Genet       Date:  2018-07-28       Impact factor: 3.412

3.  [Spontaneous endogenous LH increase in the stimulated cycle].

Authors:  H Alexander; M Birkhäuser; G Zimmermann; P Huber; N Pavic; M Lehmann; D Baier; W Weber; K W Haake
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

4.  An 18-month survey of infertility treatment by in vitro fertilization, gamete and zygote intrafallopian transfer, and replacement of frozen-thawed embryos.

Authors:  C Staessen; M Camus; I Khan; J Smitz; L Van Waesberghe; A Wisanto; P Devroey; A C Van Steirteghem
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-02

5.  Subpopulations of human granulosa-luteal cells obtained from gonadotropin- or gonadotropin-releasing hormone agonist/gonadotropin-treated follicles in in vitro fertilization-embryo transfer cycles.

Authors:  K Gersak; T Tomazevic
Journal:  J Assist Reprod Genet       Date:  1999-10       Impact factor: 3.412

6.  Supernumerous oocytes transferred in gamete intrafallopian transfer (GIFT).

Authors:  G D Chen; M T Lin; M S Lee; N A Wu; C C Huang
Journal:  J Assist Reprod Genet       Date:  1993-04       Impact factor: 3.412

7.  Pituitary down-regulation using leuprolide for the intensive ovulation management of poor prognosis patients having in vitro fertilization (IVF)-related treatments.

Authors:  J M Cummins; J M Yovich; W R Edirisinghe; J L Yovich
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-12

8.  A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program.

Authors:  P G Artini; A Volpe; S Angioni; M C Galassi; C Battaglia; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

9.  A modest increase in serum progesterone levels on the day of human chorionic gonadotropin (hCG) administration may influence pregnancy rate and pregnancy loss in in vitro fertilization-embryo transfer (IVF-ET) patients.

Authors:  M Dirnfeld; S Goldman; Y Gonen; M Koifman; A Lissak; H Abramovici
Journal:  J Assist Reprod Genet       Date:  1993-02       Impact factor: 3.412

10.  Improvement of in vitro fertilisation after treatment with buserelin, an agonist of luteinising hormone releasing hormone.

Authors:  A J Rutherford; R J Subak-Sharpe; K J Dawson; R A Margara; S Franks; R M Winston
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.